연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
1397. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.
Lee YY1, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC.
Exp Mol Med. 2013 Nov 22;45:e64. doi: 10.1038/emm.2013.115.
Link
1396. Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.
Kang MJ1, Kim HP, Lee KS, Yoo YD, Kwon YT, Kim KM, Kim TY, Yi EC.
Proteomics. 2013 May;13(10-11):1714-25. doi: 10.1002/pmic.201200511. Epub 2013 Apr 23.
Link
1395. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.
Han SW1, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, Kim JI, Kim TY.
PLoS One. 2013 May 21;8(5):e64271. doi: 10.1371/journal.pone.0064271. Print 2013.
Link
1394. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW1, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.
Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.
Link
1393. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
Lee KH1, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY.
Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13.
Link
1392. The beneficial effect of palliative resection in metastatic colorectal cancer.
Park JH1, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kang GH, Chie EK, Ha SW, Jeong SY, Park KJ, Park JG, Kim TY.
Br J Cancer. 2013 Apr 16;108(7):1425-31. doi: 10.1038/bjc.2013.94. Epub 2013 Mar 12.
Link
1391. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
Lira ME1, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Link
1390. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Park JH1, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS.
Clin Lung Cancer. 2013 Jul;14(4):383-9. doi: 10.1016/j.cllc.2012.10.007. Epub 2013 Jan 10.
Link
1389. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
Kim S1, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
J Thorac Oncol. 2013 Apr;8(4):415-22. doi: 10.1097/JTO.0b013e318283dcc0.
Link
1388. Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma.
Kim TM1, Kim S, Ahn YO, Lee SH, Kim DW, Heo DS.
Leuk Lymphoma. 2013 Jul 29. [Epub ahead of print]
Link